Does the media refer more to CHE or WST?

In the previous week, West Pharmaceutical Services had 6 more articles in the media than Chemed. MarketBeat recorded 15 mentions for West Pharmaceutical Services and 9 mentions for Chemed. Chemed's average media sentiment score of 1.04 beat West Pharmaceutical Services' score of 0.88 indicating that Chemed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Chemed 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive West Pharmaceutical Services 9 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer EHC or WST?

In the previous week, West Pharmaceutical Services had 10 more articles in the media than Encompass Health. MarketBeat recorded 15 mentions for West Pharmaceutical Services and 5 mentions for Encompass Health. Encompass Health's average media sentiment score of 0.93 beat West Pharmaceutical Services' score of 0.88 indicating that Encompass Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Encompass Health 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive West Pharmaceutical Services 9 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MDLN or WST?

In the previous week, West Pharmaceutical Services had 4 more articles in the media than Medline. MarketBeat recorded 15 mentions for West Pharmaceutical Services and 11 mentions for Medline. Medline's average media sentiment score of 1.05 beat West Pharmaceutical Services' score of 0.88 indicating that Medline is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medline 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive West Pharmaceutical Services 9 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor WST or ALC?

In the previous week, West Pharmaceutical Services had 13 more articles in the media than Alcon. MarketBeat recorded 15 mentions for West Pharmaceutical Services and 2 mentions for Alcon. West Pharmaceutical Services' average media sentiment score of 0.88 beat Alcon's score of -0.50 indicating that West Pharmaceutical Services is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment West Pharmaceutical Services 9 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alcon 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

Does the media refer more to SOLV or WST?

In the previous week, West Pharmaceutical Services had 8 more articles in the media than Solventum. MarketBeat recorded 15 mentions for West Pharmaceutical Services and 7 mentions for Solventum. Solventum's average media sentiment score of 1.34 beat West Pharmaceutical Services' score of 0.88 indicating that Solventum is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solventum 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive West Pharmaceutical Services 9 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

West Pharmaceutical Services (WST) Competitors

$345.49 +1.24 (+0.36%)

Closing price 09/11/2026 03:58 PM Eastern

Extended Trading

$346.12 +0.62 (+0.18%)

As of 09/11/2026 07:32 PM Eastern

Compare

WST vs. CHE, EHC, MDLN, ALC, and SOLV

Should you buy West Pharmaceutical Services stock or one of its competitors? West Pharmaceutical Services's main competitors and comparable companies include Chemed (CHE), Encompass Health (EHC), Medline (MDLN), Alcon (ALC), and Solventum (SOLV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does West Pharmaceutical Services compare to Chemed?

Chemed (NYSE:CHE) and West Pharmaceutical Services (NYSE:WST) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, risk, analyst recommendations, earnings and institutional ownership.

Chemed pays an annual dividend of $2.80 per share and has a dividend yield of 0.5%. West Pharmaceutical Services pays an annual dividend of $0.88 per share and has a dividend yield of 0.3%. Chemed pays out 14.1% of its earnings in the form of a dividend. West Pharmaceutical Services pays out 11.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Chemed has increased its dividend for 16 consecutive years. Chemed is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

95.8% of Chemed shares are owned by institutional investors. Comparatively, 93.9% of West Pharmaceutical Services shares are owned by institutional investors. 3.3% of Chemed shares are owned by insiders. Comparatively, 0.6% of West Pharmaceutical Services shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

West Pharmaceutical Services has higher revenue and earnings than Chemed. Chemed is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemed	$2.60B	2.59	$265.24M	$19.91	25.87
West Pharmaceutical Services	$3.33B	7.31	$493.70M	$7.81	44.24

Chemed presently has a consensus price target of $530.75, suggesting a potential upside of 3.02%. West Pharmaceutical Services has a consensus price target of $373.85, suggesting a potential upside of 8.21%. Given West Pharmaceutical Services' stronger consensus rating and higher probable upside, analysts plainly believe West Pharmaceutical Services is more favorable than Chemed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemed	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17
West Pharmaceutical Services	0 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.87

In the previous week, West Pharmaceutical Services had 6 more articles in the media than Chemed. MarketBeat recorded 15 mentions for West Pharmaceutical Services and 9 mentions for Chemed. Chemed's average media sentiment score of 1.04 beat West Pharmaceutical Services' score of 0.88 indicating that Chemed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Chemed	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
West Pharmaceutical Services	9 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

West Pharmaceutical Services has a net margin of 16.98% compared to Chemed's net margin of 10.60%. Chemed's return on equity of 31.77% beat West Pharmaceutical Services' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemed	10.60%	31.77%	18.90%
West Pharmaceutical Services	16.98%	20.11%	14.83%

Chemed has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market. Comparatively, West Pharmaceutical Services has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market.

Summary

West Pharmaceutical Services beats Chemed on 12 of the 20 factors compared between the two stocks.

How does West Pharmaceutical Services compare to Encompass Health?

Encompass Health (NYSE:EHC) and West Pharmaceutical Services (NYSE:WST) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment.

In the previous week, West Pharmaceutical Services had 10 more articles in the media than Encompass Health. MarketBeat recorded 15 mentions for West Pharmaceutical Services and 5 mentions for Encompass Health. Encompass Health's average media sentiment score of 0.93 beat West Pharmaceutical Services' score of 0.88 indicating that Encompass Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Encompass Health	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
West Pharmaceutical Services	9 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Encompass Health pays an annual dividend of $0.84 per share and has a dividend yield of 0.7%. West Pharmaceutical Services pays an annual dividend of $0.88 per share and has a dividend yield of 0.3%. Encompass Health pays out 13.7% of its earnings in the form of a dividend. West Pharmaceutical Services pays out 11.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Encompass Health has raised its dividend for 2 consecutive years. Encompass Health is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

West Pharmaceutical Services has a net margin of 16.98% compared to Encompass Health's net margin of 10.01%. West Pharmaceutical Services' return on equity of 20.11% beat Encompass Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Encompass Health	10.01%	18.08%	8.22%
West Pharmaceutical Services	16.98%	20.11%	14.83%

Encompass Health presently has a consensus target price of $146.83, suggesting a potential upside of 20.72%. West Pharmaceutical Services has a consensus target price of $373.85, suggesting a potential upside of 8.21%. Given Encompass Health's stronger consensus rating and higher probable upside, equities analysts plainly believe Encompass Health is more favorable than West Pharmaceutical Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Encompass Health	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00
West Pharmaceutical Services	0 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.87

Encompass Health has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market. Comparatively, West Pharmaceutical Services has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market.

97.3% of Encompass Health shares are held by institutional investors. Comparatively, 93.9% of West Pharmaceutical Services shares are held by institutional investors. 1.8% of Encompass Health shares are held by company insiders. Comparatively, 0.6% of West Pharmaceutical Services shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Encompass Health has higher revenue and earnings than West Pharmaceutical Services. Encompass Health is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Encompass Health	$6.21B	1.93	$566.20M	$6.14	19.81
West Pharmaceutical Services	$3.33B	7.31	$493.70M	$7.81	44.24

Summary

West Pharmaceutical Services beats Encompass Health on 10 of the 19 factors compared between the two stocks.

How does West Pharmaceutical Services compare to Medline?

Medline (NASDAQ:MDLN) and West Pharmaceutical Services (NYSE:WST) are both large-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability and earnings.

In the previous week, West Pharmaceutical Services had 4 more articles in the media than Medline. MarketBeat recorded 15 mentions for West Pharmaceutical Services and 11 mentions for Medline. Medline's average media sentiment score of 1.05 beat West Pharmaceutical Services' score of 0.88 indicating that Medline is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medline	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
West Pharmaceutical Services	9 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

93.9% of West Pharmaceutical Services shares are owned by institutional investors. 0.8% of Medline shares are owned by company insiders. Comparatively, 0.6% of West Pharmaceutical Services shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

West Pharmaceutical Services has a net margin of 16.98% compared to Medline's net margin of 0.00%. West Pharmaceutical Services' return on equity of 20.11% beat Medline's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medline	N/A	N/A	N/A
West Pharmaceutical Services	16.98%	20.11%	14.83%

Medline presently has a consensus target price of $47.42, suggesting a potential upside of 45.78%. West Pharmaceutical Services has a consensus target price of $373.85, suggesting a potential upside of 8.21%. Given Medline's higher possible upside, research analysts plainly believe Medline is more favorable than West Pharmaceutical Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medline	1 Sell rating(s)	5 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.83
West Pharmaceutical Services	0 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.87

Medline has higher revenue and earnings than West Pharmaceutical Services. Medline is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medline	$28.43B	1.50	$1.16B	$0.79	41.18
West Pharmaceutical Services	$3.33B	7.31	$493.70M	$7.81	44.24

Summary

West Pharmaceutical Services beats Medline on 9 of the 16 factors compared between the two stocks.

How does West Pharmaceutical Services compare to Alcon?

West Pharmaceutical Services (NYSE:WST) and Alcon (NYSE:ALC) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings.

West Pharmaceutical Services has a net margin of 16.98% compared to Alcon's net margin of 5.92%. West Pharmaceutical Services' return on equity of 20.11% beat Alcon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
West Pharmaceutical Services	16.98%	20.11%	14.83%
Alcon	5.92%	7.29%	5.09%

93.9% of West Pharmaceutical Services shares are owned by institutional investors. Comparatively, 53.9% of Alcon shares are owned by institutional investors. 0.6% of West Pharmaceutical Services shares are owned by insiders. Comparatively, 1.5% of Alcon shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Alcon has higher revenue and earnings than West Pharmaceutical Services. West Pharmaceutical Services is trading at a lower price-to-earnings ratio than Alcon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
West Pharmaceutical Services	$3.33B	7.31	$493.70M	$7.81	44.24
Alcon	$10.86B	3.01	$980M	$1.31	50.43

West Pharmaceutical Services has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market. Comparatively, Alcon has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market.

In the previous week, West Pharmaceutical Services had 13 more articles in the media than Alcon. MarketBeat recorded 15 mentions for West Pharmaceutical Services and 2 mentions for Alcon. West Pharmaceutical Services' average media sentiment score of 0.88 beat Alcon's score of -0.50 indicating that West Pharmaceutical Services is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
West Pharmaceutical Services	9 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alcon	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

West Pharmaceutical Services presently has a consensus target price of $373.85, suggesting a potential upside of 8.21%. Alcon has a consensus target price of $84.96, suggesting a potential upside of 28.60%. Given Alcon's higher probable upside, analysts plainly believe Alcon is more favorable than West Pharmaceutical Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
West Pharmaceutical Services	0 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.87
Alcon	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.61

Summary

West Pharmaceutical Services beats Alcon on 11 of the 16 factors compared between the two stocks.

How does West Pharmaceutical Services compare to Solventum?

Solventum (NYSE:SOLV) and West Pharmaceutical Services (NYSE:WST) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Solventum has a net margin of 17.26% compared to West Pharmaceutical Services' net margin of 16.98%. Solventum's return on equity of 25.09% beat West Pharmaceutical Services' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solventum	17.26%	25.09%	8.78%
West Pharmaceutical Services	16.98%	20.11%	14.83%

Solventum has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market. Comparatively, West Pharmaceutical Services has a beta of 1.14, meaning that its stock price is 14% more volatile than the broader market.

93.9% of West Pharmaceutical Services shares are owned by institutional investors. 0.2% of Solventum shares are owned by insiders. Comparatively, 0.6% of West Pharmaceutical Services shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, West Pharmaceutical Services had 8 more articles in the media than Solventum. MarketBeat recorded 15 mentions for West Pharmaceutical Services and 7 mentions for Solventum. Solventum's average media sentiment score of 1.34 beat West Pharmaceutical Services' score of 0.88 indicating that Solventum is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solventum	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
West Pharmaceutical Services	9 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Solventum currently has a consensus target price of $92.80, suggesting a potential upside of 6.15%. West Pharmaceutical Services has a consensus target price of $373.85, suggesting a potential upside of 8.21%. Given West Pharmaceutical Services' stronger consensus rating and higher probable upside, analysts clearly believe West Pharmaceutical Services is more favorable than Solventum.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solventum	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
West Pharmaceutical Services	0 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.87

Solventum has higher revenue and earnings than West Pharmaceutical Services. Solventum is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solventum	$8.33B	1.79	$1.56B	$8.18	10.69
West Pharmaceutical Services	$3.33B	7.31	$493.70M	$7.81	44.24

Summary

West Pharmaceutical Services beats Solventum on 11 of the 17 factors compared between the two stocks.

Get West Pharmaceutical Services News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

WST vs. The Competition

Export

Metric	West Pharmaceutical Services	Healthcare Equipment & Supplies Industry	Healthcare Sector	NYSE Exchange
Market Cap	$24.23B	$5.42B	$7.15B	$23.19B
Dividend Yield	0.26%	1.79%	2.56%	3.56%
P/E Ratio	44.24	24.86	274.10	28.71
Price / Sales	7.31	82.29	655.45	94.44
Price / Cash	35.35	32.53	77.04	33.82
Price / Book	7.83	5.97	10.33	4.74
Net Income	$493.70M	$150.14M	$3.50B	$1.07B
7 Day Performance	1.65%	-2.83%	-3.33%	-2.00%
1 Month Performance	-1.86%	-3.09%	-0.41%	-2.69%
1 Year Performance	36.29%	9.34%	19.22%	10.45%

West Pharmaceutical Services Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
WST West Pharmaceutical Services	3.6606 of 5 stars	$345.49 +0.4%	$373.85 +8.2%	+31.1%	$24.23B	$3.33B	44.24	10,800	Analyst Forecast Insider Trade
CHE Chemed	4.4165 of 5 stars	$520.82 +0.2%	$530.75 +1.9%	+12.5%	$6.79B	$2.53B	26.16	15,811	Positive News
EHC Encompass Health	4.7315 of 5 stars	$121.80 +0.0%	$148.71 +22.1%	-4.1%	$12.02B	$5.94B	19.84	42,000
MDLN Medline	3.6123 of 5 stars	$36.59 flat	$47.42 +29.6%	N/A	$48.11B	$28.43B	46.32	45,000	Positive News
ALC Alcon	3.1607 of 5 stars	$70.54 +0.1%	$84.96 +20.4%	-17.0%	$34.87B	$10.40B	53.85	25,942

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:WST) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

West Pharmaceutical Services (WST) Competitors

WST vs. CHE, EHC, MDLN, ALC, and SOLV

How does West Pharmaceutical Services compare to Chemed?

Summary

How does West Pharmaceutical Services compare to Encompass Health?

Summary

How does West Pharmaceutical Services compare to Medline?

Summary

How does West Pharmaceutical Services compare to Alcon?

Summary

How does West Pharmaceutical Services compare to Solventum?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WST vs. The Competition

West Pharmaceutical Services Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

West Pharmaceutical Services (WST) Competitors

WST vs. CHE, EHC, MDLN, ALC, and SOLV

How does West Pharmaceutical Services compare to Chemed?

Is CHE or WST a better dividend stock?

Do insiders & institutionals have more ownership in CHE or WST?

Which has higher earnings and valuation, CHE or WST?

Do analysts recommend CHE or WST?

Does the media refer more to CHE or WST?

Is CHE or WST more profitable?

Which has more risk & volatility, CHE or WST?

Summary

How does West Pharmaceutical Services compare to Encompass Health?

Does the media prefer EHC or WST?

Is EHC or WST a better dividend stock?

Is EHC or WST more profitable?

Do analysts rate EHC or WST?

Which has more risk & volatility, EHC or WST?

Do insiders & institutionals believe in EHC or WST?

Which has higher earnings & valuation, EHC or WST?

Summary

How does West Pharmaceutical Services compare to Medline?

Does the media prefer MDLN or WST?

Do insiders and institutionals hold more shares of MDLN or WST?

Is MDLN or WST more profitable?

Do analysts prefer MDLN or WST?

Which has stronger earnings and valuation, MDLN or WST?

Summary

How does West Pharmaceutical Services compare to Alcon?

Is WST or ALC more profitable?

Do insiders and institutionals hold more shares of WST or ALC?

Which has higher earnings & valuation, WST or ALC?

Which has more risk & volatility, WST or ALC?

Does the media favor WST or ALC?

Do analysts rate WST or ALC?

Summary

How does West Pharmaceutical Services compare to Solventum?

Is SOLV or WST more profitable?

Which has more volatility and risk, SOLV or WST?

Do insiders & institutionals have more ownership in SOLV or WST?

Does the media refer more to SOLV or WST?

Do analysts recommend SOLV or WST?

Which has better earnings and valuation, SOLV or WST?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WST vs. The Competition

West Pharmaceutical Services Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools